Exscientia and GT Apeiron Therapeutics Enter Oncology Joint Venture

Combines Exscientia’s leading AI-driven drug identification and design capabilities with GT Apeiron’s expertise in cyclin-dependent kinase (CDK) targets for oncology Expands existing CDK7 drug discovery partnership with additional CDK targeting drugs...

Full "IntellAsia: Resources" article